
Piramal Pharma Reports 17% Revenue Growth Amid Margin Expansion
Piramal Pharma Limited posted a 17% increase in revenue for the first quarter of fiscal year 2027, reaching ₹2,270 crore. The Mumbai-based firm saw its EBITDA jump 72% to ₹285 crore, as the company benefited from improved operating leverage and sustained performance across its CDMO, hospital generics, and consumer health divisions.

























